R M Parks1,2, M A Albanghali3,4, B M Syed3,5, A R Green3, I O Ellis3, K-L Cheung3. 1. Nottingham Breast Cancer Research Centre, University of Nottingham, Nottingham, UK. ruth.parks@nottingham.ac.uk. 2. School of Medicine, Royal Derby Hospital Centre, University of Nottingham, Uttoxeter Road, Derby, DE22 3DT, UK. ruth.parks@nottingham.ac.uk. 3. Nottingham Breast Cancer Research Centre, University of Nottingham, Nottingham, UK. 4. Public Health Department, Faculty of Applied Medical Sciences, Albaha University, Al Bahah, Saudi Arabia. 5. Medical Research Centre, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
Abstract
PURPOSE: Prediction of response to primary endocrine therapy (PET) in older women is based on measurement of oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor (HER)-2. This study uses a unique method for construction of core needle biopsy (CNB) tissue microarray (TMA), to correlate expression of a panel of 17 biomarkers with clinical outcome, in patients receiving PET. METHODS: Over 37 years (1973-2010), 1758 older (≥ 70 years) women with operable primary breast cancer were managed in a single institution. Of these, 693 had sufficient good-quality CNB to construct TMA, of which 334 had ER-positive tumours treated by PET with a minimum of 6-month follow-up. A panel of biomarkers was measured by immunohistochemistry (ER, PgR, HER2, Ki-67, p53, CK5/6, CK 7/8, EGFR, BCL-2, MUC1, VEGF, LKB1, BRCA1, HER3, HER4, PTEN and AIB1). Expression of each biomarker was dichotomised into 'low' or 'high' based on breast cancer-specific survival (BCSS). RESULTS: From the panel of biomarkers, multivariate analysis showed: High ER (p = 0.003) and PgR (p = 0.002) were associated with clinical benefit of PET at 6 months, as opposed to progressive disease. High ER (p = 0.0023), PgR (p < 0.001) and BCL-2 (p = 0.043) and low LKB1 (p = 0.022) were associated with longer time to progression. High PgR (p < 0.001) and low MUC1 (p = 0.021) were associated with better BCSS. Expression of other biomarkers did not show any significant correlation. CONCLUSIONS: In addition to ER and PgR; MUC1, BCL-2 and LKB1 are important in determining the outcome of PET in this cohort.
PURPOSE: Prediction of response to primary endocrine therapy (PET) in older women is based on measurement of oestrogen receptor (ER), progesterone receptor (PgR) and humanepidermal growth factor (HER)-2. This study uses a unique method for construction of core needle biopsy (CNB) tissue microarray (TMA), to correlate expression of a panel of 17 biomarkers with clinical outcome, in patients receiving PET. METHODS: Over 37 years (1973-2010), 1758 older (≥ 70 years) women with operable primary breast cancer were managed in a single institution. Of these, 693 had sufficient good-quality CNB to construct TMA, of which 334 had ER-positive tumours treated by PET with a minimum of 6-month follow-up. A panel of biomarkers was measured by immunohistochemistry (ER, PgR, HER2, Ki-67, p53, CK5/6, CK 7/8, EGFR, BCL-2, MUC1, VEGF, LKB1, BRCA1, HER3, HER4, PTEN and AIB1). Expression of each biomarker was dichotomised into 'low' or 'high' based on breast cancer-specific survival (BCSS). RESULTS: From the panel of biomarkers, multivariate analysis showed: High ER (p = 0.003) and PgR (p = 0.002) were associated with clinical benefit of PET at 6 months, as opposed to progressive disease. High ER (p = 0.0023), PgR (p < 0.001) and BCL-2 (p = 0.043) and low LKB1 (p = 0.022) were associated with longer time to progression. High PgR (p < 0.001) and low MUC1 (p = 0.021) were associated with better BCSS. Expression of other biomarkers did not show any significant correlation. CONCLUSIONS: In addition to ER and PgR; MUC1, BCL-2 and LKB1 are important in determining the outcome of PET in this cohort.
Authors: Dalia M Abd El-Rehim; Graham Ball; Sarah E Pinder; Emad Rakha; Claire Paish; John F R Robertson; Douglas Macmillan; Roger W Blamey; Ian O Ellis Journal: Int J Cancer Date: 2005-09-01 Impact factor: 7.396
Authors: Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark Journal: Breast Cancer Res Treat Date: 2006-08-24 Impact factor: 4.872
Authors: Luke Piggott; Andreia Silva; Timothy Robinson; Angelica Santiago-Gómez; Bruno M Simões; Michael Becker; Iduna Fichtner; Ladislav Andera; Philippa Young; Christine Morris; Peter Barrett-Lee; Fouad Alchami; Marco Piva; Maria dM Vivanco; Robert B Clarke; Julia Gee; Richard Clarkson Journal: Clin Cancer Res Date: 2018-01-23 Impact factor: 12.531
Authors: Ruth M Parks; Mohammad Albanghali; Binafsha M Syed; Andrew R Green; Ian O Ellis; Kwok-Leung Cheung Journal: Cancers (Basel) Date: 2020-07-27 Impact factor: 6.639
Authors: Małgorzata Szostakowska; Alicja Trębińska-Stryjewska; Ewa Anna Grzybowska; Anna Fabisiewicz Journal: Breast Cancer Res Treat Date: 2018-11-01 Impact factor: 4.872